MS drug prevented fatal heart condition in lab study

January 30, 2012 in Cardiology

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

Scientists found that Gilenya, a drug recently approved in the US for treating MS, was effective at reversing the symptoms of ventricular hypertrophy in mice.

Ventricular hypertrophy is a fatal cardiac disorder that can result in an (arrhythmia) and cardiac arrest. It is caused by sustained pressure on the due to stresses or diseases, such as hypertension (), valvular heart disease or (heart attack), and is the leading cause of worldwide.

Researchers from The University of Manchester and the University of Illinois at Chicago have discovered that enhancing the activity of an enzyme molecule called Pak1 that is found naturally in our bodies using Gilenya produced remarkable results in mice with ventricular hypertrophy.

Study co-author Dr Xin Wang, a Lecturer in Molecular Cardiology in Manchester's Faculty of Life Sciences, said: " is the pathological state to respond to sustained stresses on the heart resulting in increases in ventricular wall thickness and muscle mass of the heart. The condition is often associated with fatal complications, such as, and rhythm disorders, such as ventricular arrhythmias, leading to millions of deaths worldwide each year.

"Our research had previously identified the effect of Pak1 in preventing tissue damage caused by reduced blood flow to the heart, known as cardiac ischemic injury. This latest study used mice with a genetic modification of the Pak1 gene to show how the enzyme, when stimulated by Gilenya, prevented and even reversed the symptoms of ventricular hypertrophy."

The research, led in Manchester by Dr Ming Lei, Dr Xin Wang and Dr Elizabeth Cartwright, and in Chicago by Professor John Solaro and Dr Yunbo Ke, is published in the leading cardiovascular journal, Circulation.

Dr Lei, who is based in Manchester's Faculty of Medical and Human Sciences, added: "In recent years, escalating costs, risks, and uncertainty associated with drug development for treating cardiovascular diseases have posed daunting challenges to the pharmaceutical industry. Our discovery opens up fresh avenues for developing a new class of drug for treating several fatal heart conditions. The novel effect of this existing drug means that we have the potential to accelerate the availability of a new therapy for patients with these heart conditions."

More information: 'Pak1 as a Novel Therapeutic Target for Antihypertrophic Treatment in the Heart,' published in Circulation, doi:10.1161/CIRCULATIONAHA.111.048785

Journal reference: Circulation search and more info website

Provided by University of Manchester search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Dual-source cardiac CT IDs CAD in hard-to-image patients

(HealthDay)—In patients who have previously been considered difficult to image, dual-source cardiac (DSC) computed tomography (CT) can identify clinically significant coronary artery disease, according ...

Cardiology created 6 hours ago | popularity not rated yet | comments 0

Death rates decline for advanced heart failure patients, but outcomes are still not ideal

UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden ...

Cardiology created 9 hours ago | popularity not rated yet | comments 0

Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II

22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...

Cardiology created 14 hours ago | popularity not rated yet | comments 0

Costs to treat stroke in America may double by 2030

Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.

Cardiology created May 22, 2013 | popularity not rated yet | comments 0

New blood-thinner measures may cut medication errors

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Cardiology created May 22, 2013 | popularity not rated yet | comments 0


Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

ACP issues recommendations for management of high blood glucose in hospitalized patients

High blood glucose is associated with poor outcomes in hospitalized patients, and use of intensive insulin therapy (IIT) to control hyperglycemia is a common practice in hospitals. But the recent evidence does not show a ...

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...